Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
Authors:
Open Access
- 26 July 2022
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 12 (7) , 1-5
Abstract
No abstract availableKeywords
Funding Information
- Fraternal Order of Eagles
- Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic
This publication has 14 references indexed in Scilit:
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2020
- Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T CellsTransplantation and Cellular Therapy, 2020
- MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TREATMENT WITH CD19 TARGETED CAR‐T CELL THERAPY IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOMAHematological Oncology, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myelomaLeukemia Research, 2018
- Chimeric Antigen Receptor TherapyNew England Journal of Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Therapy-related myeloid neoplasms: when genetics and environment collideNature Reviews Cancer, 2017
- Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma PatientsJournal of Clinical Oncology, 2003
- Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid MalignanciesJournal of Clinical Oncology, 2000